Manufacturing authorization for conjugate vaccines

celares has equipped its manufacturing unit for the production of conjugate vaccines for the use in clinical trials. After a successful inspection of the facility in November 2020 celares has now obtained a GMP certificate and a manufacturing authorization for conjugate vaccine drug substance for the preparation of investigational medicinal products (IMP) to be tested in clinical trials.